Get started
Author

Gloria R. Olivier

Observed names: Gloria Olivier, Olivier Gloria
Institution: Mayo Clinic
ORCID: 0000-0002-6870-6056
Observed ORCID: 0000-0002-6870-6056
OpenAlex ID: A5019215565
Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice
2022 · Laura Evgin, Tim Kottke, et al. · Science Translational Medicine · 209
Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression
2024 · Olivia Sirpilla, R. Leo Sakemura, et al. · Nature Biomedical Engineering · 43
PDF
Comparison of replicating and nonreplicating vaccines against SARS-CoV-2
2022 · Haley E. Mudrick, Shane Massey, et al. · Science Advances · 15
Favorable Modulation of Chimeric Antigen Receptor T Cells Safety and Efficacy By the Non-Covalent BTK Inhibitor Vecabrutinib
2021 · Mohamad M. Adada, Reona Sakemura, et al. · Blood · 4
Comparison of Mucosal and Intramuscular Immunization against SARS-CoV-2 with Replication-Defective and Replicating Single-cycle Adenovirus Vaccines
2021 · Haley E. Mudrick, Erin B. McGlinch, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 4
PDF
324 Sensitizing poorly differentiated thyroid cancers to TSHR-CART cell therapy with MEK inhibitors
2022 · John Copland, Kendall Schick, et al. · Regular and Young Investigator Award Abstracts · 2
PDF
TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma
2021 · Claudia Manriquez Roman, Michelle J. Cox, et al. · Blood · 2
Redifferentiation-enabled TSHRCART cells overcome antigen loss in aggressive thyroid cancers
2026 · Claudia Manriquez-Roman, Elizabeth L. Siegler, et al. · Molecular Cancer
Abstract 5074: Addition of MAPK inhibitors to prime and sensitize poorly differentiated thyroid cancers as a strategy to improve TSHR-CART cell therapy antitumor activity
2023 · Claudia Manriquez Roman, Kendall J. Schick, et al. · Cancer Research
Works count: 9
Citation count: 279
H-index: 4
I10-index: 3
Year
Topic
Type